ABOS - CIK 0001576885
Acumen Pharmaceuticals, Inc. trades as ABOS. This page tracks Acumen Pharmaceuticals, Inc. through 336 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-12 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Proxy statement | DEF 14A | 2026-04-23 |
| SCHEDULE 13G | - | 2026-04-07 |
| EFFECT | - | 2026-04-01 |
| 424B3 | - | 2026-04-01 |
The largest companies sharing Acumen Pharmaceuticals, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
In its latest fiscal year Acumen Pharmaceuticals, Inc. reported a net loss of $121.33M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.